Serratus Anterior Plane Block with Methylene Blue and Ropivacaine for Analgesia in Prosthetic Breast Augmentation: A Randomized Controlled Trial

What Was Tested

This randomized controlled trial paper looks at Methylene blue (non-peptide stack partner).

The visual analog scale was used to assess pain scores, which were observed and recorded at 6, 24, 48, and 72 hours postoperatively by 2 well-trained, independent investigators.

Why It Was Studied

Pain is a prominent symptom following prosthetic breast augmentation by means of axillary incision, and persists throughout hospitalization.

Duration of regional block with ropivacaine is also limited.

Who Took Part

The abstract describes 72 patients taking part.

PubMed indexes the participants as adults and middle-aged adults, women only.

This double-blind, single-center, randomized controlled trial enrolled 72 female patients, who were randomly and equally assigned to the control group, the ropivacaine group, and the ropivacaine plus methylene blue group during surgery.

A standard postoperative analgesic regimen was administered to all patients.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

The patients were allocated by chance, so the Methylene blue (non-peptide stack partner) group and the comparison group should start out alike.

As a double-blind Methylene blue (non-peptide stack partner) study, the assignments were hidden from both participants and investigators until the end.

What Was Measured

Topics PubMed links to this paper include Ropivacaine, Methylene Blue, Postoperative Pain, Anesthetics, Local, Nerve Block, Pain Measurement and Breast Implantation.

What This Means in Plain Language

The paper is a randomized and double-blind study of Methylene blue (non-peptide stack partner) in 72 patients.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Plastic and reconstructive surgery), a journal based in United States.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.